Trials / Terminated
TerminatedNCT02886858
tDCS in the Prevention of Relapse After Electroconvulsive Therapy
tDCS as Continuation Treatment to Sustain Remission After Electroconvulsive Therapy in Depression
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Hôpital le Vinatier · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
While electroconvulsive therapy (ECT) in major depression is effective, high relapse rates and cognitive side effects limit its long-term use. There is no consensus about optimal continuation pharmacological treatments after a ECT course. Adjunction of tDCS to pharmacological continuation treatment after ECT may decrease relapse rates.
Detailed description
In a prospective, randomized, double blind, controlled, long-term study, investigators assign 40 depressed patients, in remission after ECT course associated to venlafaxine, with lithium adjunction after ECT course, either to tDCS or sham tDCS. Depressive symptoms and cognition were assessed after acute ECT after six months of continuation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Device : Transcranial direct current stimulation | The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months. |
| DEVICE | Device : sham Transcranial direct current stimulation | The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months. |
Timeline
- Start date
- 2017-02-13
- Primary completion
- 2019-04-19
- Completion
- 2019-04-19
- First posted
- 2016-09-01
- Last updated
- 2019-04-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02886858. Inclusion in this directory is not an endorsement.